Clinical Trials Browser

Neuroendocrine Tumors × sintilimab × Clear all

NCT05165407 2025-03-14

NESSIE

Phase 2 Recruiting

Neuroendocrine Tumors

NCT05113355 2021-11-24

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Phase 2 Unknown

Carcinoma, Neuroendocrine, Neuroendocrine Tumors